



**Fig. S1. Proportion of patients with moderate-to-severe psoriasis achieving complete clearance of their nail psoriasis (Nail Psoriasis Severity Index (NAPSI)=0) (observed) at each post-baseline visit up to week 264.** Data presented as observed. Symbols in line graphs are offset horizontally to differentiate overlapping data points.



**Fig. S2. Mean improvement in overall Nail Psoriasis Severity Index (NAPSI) score (observed) of adult patients with moderate-to-severe psoriasis treated with ixekizumab (IXE) during 264 weeks in patients with baseline nail psoriasis (NAPSI  $\geq 1$ ; N=219; grey) and the subgroup of patients with significant baseline nail psoriasis (NAPSI  $\geq 16$  and  $\geq 4$  fingernails involved; n=134/219; red). N: number of patients.**



**Fig. S3. Mean improvement (observed) in overall Nail Psoriasis Severity Index (NAPSI) score (Observed), nail bed (solid line) and nail matrix features (dotted line) of adult patients with moderate-to-severe psoriasis treated with ixekizumab (IXE) during 264 weeks in patients with baseline nail psoriasis (NAPSI  $\geq 1$ ; N=219; grey) and the subgroup of patients with significant baseline nail psoriasis (NAPSI  $\geq 16$  and  $\geq 4$  fingernails involved; n=134/219; red). N: number of patients.**

